Patterns of the hazard of death after AIDS through the evolution of antiretroviral therapy

1984-2004

Michael F. Schneider, Stephen J. Gange, Carolyn M. Williams, Kathryn Anastos, Ruth M. Greenblatt, Lawrence Kingsley, Roger Detels, Alvaro Muñoz

Research output: Contribution to journalArticle

102 Citations (Scopus)

Abstract

Objective: To characterize changing survival patterns after development of clinical AIDS from 1984 to 2004, when different antiretroviral therapies were being introduced. Design: Cohort of homosexual men since 1984 and cohort of women since 1994. Methods: A total of 1504 men and 461 women were followed for all-cause mortality after an incident AIDS diagnosis. Relative hazards of death and relative times to death were determined in five therapy eras: no/monotherapy (July 1984-December 1989), monotherapy/combination therapy (January 1990-December 1994), HAART introduction (January 1995-June 1998), short-term stable HAART use (July 1998-June 2001), and moderate-term stable HAART use (July 2001-December 2003). Results: A total of 1057 (54%) study participants died. The time at which 25% of individuals died after an AIDS diagnosis increased significantly from 0.56 years [95% confidence interval (CI), 0.50-0.64] in the no/monotherapy era to 0.74 (95% CI, 0.67-0.82), 1.78 (95% CI, 1.29-2.44), 4.22 (95% CI, 2.94-6.05) and 5.08 years (95% CI, 2.39-10.79) in the four subsequent therapy eras, respectively. Inferences on the beneficial effects of HAART were confirmed after adjustment by age, sex, type of AIDS diagnosis and CD4 cell count at diagnosis. The pattern of the hazard of death after AIDS changed from increasing in the pre-HAART era to being lower and non-increasing in the eras of HAART. Conclusions: The sustained beneficial effect of HAART, even in individuals with clinical AIDS and extensive treatment histories, attenuates concerns about emergence of resistance but augurs that a substantial number of HIV-infected individuals may require care for very long periods.

Original languageEnglish (US)
Pages (from-to)2009-2018
Number of pages10
JournalAIDS
Volume19
Issue number17
StatePublished - Nov 2005

Fingerprint

Highly Active Antiretroviral Therapy
Acquired Immunodeficiency Syndrome
Confidence Intervals
Therapeutics
CD4 Lymphocyte Count
HIV
Survival
Mortality

Keywords

  • AIDS
  • Effectiveness
  • HAART
  • Hazard
  • Survival

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Schneider, M. F., Gange, S. J., Williams, C. M., Anastos, K., Greenblatt, R. M., Kingsley, L., ... Muñoz, A. (2005). Patterns of the hazard of death after AIDS through the evolution of antiretroviral therapy: 1984-2004. AIDS, 19(17), 2009-2018.

Patterns of the hazard of death after AIDS through the evolution of antiretroviral therapy : 1984-2004. / Schneider, Michael F.; Gange, Stephen J.; Williams, Carolyn M.; Anastos, Kathryn; Greenblatt, Ruth M.; Kingsley, Lawrence; Detels, Roger; Muñoz, Alvaro.

In: AIDS, Vol. 19, No. 17, 11.2005, p. 2009-2018.

Research output: Contribution to journalArticle

Schneider, MF, Gange, SJ, Williams, CM, Anastos, K, Greenblatt, RM, Kingsley, L, Detels, R & Muñoz, A 2005, 'Patterns of the hazard of death after AIDS through the evolution of antiretroviral therapy: 1984-2004', AIDS, vol. 19, no. 17, pp. 2009-2018.
Schneider MF, Gange SJ, Williams CM, Anastos K, Greenblatt RM, Kingsley L et al. Patterns of the hazard of death after AIDS through the evolution of antiretroviral therapy: 1984-2004. AIDS. 2005 Nov;19(17):2009-2018.
Schneider, Michael F. ; Gange, Stephen J. ; Williams, Carolyn M. ; Anastos, Kathryn ; Greenblatt, Ruth M. ; Kingsley, Lawrence ; Detels, Roger ; Muñoz, Alvaro. / Patterns of the hazard of death after AIDS through the evolution of antiretroviral therapy : 1984-2004. In: AIDS. 2005 ; Vol. 19, No. 17. pp. 2009-2018.
@article{0ab129febfde4bd7934de3c474e154f6,
title = "Patterns of the hazard of death after AIDS through the evolution of antiretroviral therapy: 1984-2004",
abstract = "Objective: To characterize changing survival patterns after development of clinical AIDS from 1984 to 2004, when different antiretroviral therapies were being introduced. Design: Cohort of homosexual men since 1984 and cohort of women since 1994. Methods: A total of 1504 men and 461 women were followed for all-cause mortality after an incident AIDS diagnosis. Relative hazards of death and relative times to death were determined in five therapy eras: no/monotherapy (July 1984-December 1989), monotherapy/combination therapy (January 1990-December 1994), HAART introduction (January 1995-June 1998), short-term stable HAART use (July 1998-June 2001), and moderate-term stable HAART use (July 2001-December 2003). Results: A total of 1057 (54{\%}) study participants died. The time at which 25{\%} of individuals died after an AIDS diagnosis increased significantly from 0.56 years [95{\%} confidence interval (CI), 0.50-0.64] in the no/monotherapy era to 0.74 (95{\%} CI, 0.67-0.82), 1.78 (95{\%} CI, 1.29-2.44), 4.22 (95{\%} CI, 2.94-6.05) and 5.08 years (95{\%} CI, 2.39-10.79) in the four subsequent therapy eras, respectively. Inferences on the beneficial effects of HAART were confirmed after adjustment by age, sex, type of AIDS diagnosis and CD4 cell count at diagnosis. The pattern of the hazard of death after AIDS changed from increasing in the pre-HAART era to being lower and non-increasing in the eras of HAART. Conclusions: The sustained beneficial effect of HAART, even in individuals with clinical AIDS and extensive treatment histories, attenuates concerns about emergence of resistance but augurs that a substantial number of HIV-infected individuals may require care for very long periods.",
keywords = "AIDS, Effectiveness, HAART, Hazard, Survival",
author = "Schneider, {Michael F.} and Gange, {Stephen J.} and Williams, {Carolyn M.} and Kathryn Anastos and Greenblatt, {Ruth M.} and Lawrence Kingsley and Roger Detels and Alvaro Mu{\~n}oz",
year = "2005",
month = "11",
language = "English (US)",
volume = "19",
pages = "2009--2018",
journal = "AIDS",
issn = "0269-9370",
publisher = "Lippincott Williams and Wilkins",
number = "17",

}

TY - JOUR

T1 - Patterns of the hazard of death after AIDS through the evolution of antiretroviral therapy

T2 - 1984-2004

AU - Schneider, Michael F.

AU - Gange, Stephen J.

AU - Williams, Carolyn M.

AU - Anastos, Kathryn

AU - Greenblatt, Ruth M.

AU - Kingsley, Lawrence

AU - Detels, Roger

AU - Muñoz, Alvaro

PY - 2005/11

Y1 - 2005/11

N2 - Objective: To characterize changing survival patterns after development of clinical AIDS from 1984 to 2004, when different antiretroviral therapies were being introduced. Design: Cohort of homosexual men since 1984 and cohort of women since 1994. Methods: A total of 1504 men and 461 women were followed for all-cause mortality after an incident AIDS diagnosis. Relative hazards of death and relative times to death were determined in five therapy eras: no/monotherapy (July 1984-December 1989), monotherapy/combination therapy (January 1990-December 1994), HAART introduction (January 1995-June 1998), short-term stable HAART use (July 1998-June 2001), and moderate-term stable HAART use (July 2001-December 2003). Results: A total of 1057 (54%) study participants died. The time at which 25% of individuals died after an AIDS diagnosis increased significantly from 0.56 years [95% confidence interval (CI), 0.50-0.64] in the no/monotherapy era to 0.74 (95% CI, 0.67-0.82), 1.78 (95% CI, 1.29-2.44), 4.22 (95% CI, 2.94-6.05) and 5.08 years (95% CI, 2.39-10.79) in the four subsequent therapy eras, respectively. Inferences on the beneficial effects of HAART were confirmed after adjustment by age, sex, type of AIDS diagnosis and CD4 cell count at diagnosis. The pattern of the hazard of death after AIDS changed from increasing in the pre-HAART era to being lower and non-increasing in the eras of HAART. Conclusions: The sustained beneficial effect of HAART, even in individuals with clinical AIDS and extensive treatment histories, attenuates concerns about emergence of resistance but augurs that a substantial number of HIV-infected individuals may require care for very long periods.

AB - Objective: To characterize changing survival patterns after development of clinical AIDS from 1984 to 2004, when different antiretroviral therapies were being introduced. Design: Cohort of homosexual men since 1984 and cohort of women since 1994. Methods: A total of 1504 men and 461 women were followed for all-cause mortality after an incident AIDS diagnosis. Relative hazards of death and relative times to death were determined in five therapy eras: no/monotherapy (July 1984-December 1989), monotherapy/combination therapy (January 1990-December 1994), HAART introduction (January 1995-June 1998), short-term stable HAART use (July 1998-June 2001), and moderate-term stable HAART use (July 2001-December 2003). Results: A total of 1057 (54%) study participants died. The time at which 25% of individuals died after an AIDS diagnosis increased significantly from 0.56 years [95% confidence interval (CI), 0.50-0.64] in the no/monotherapy era to 0.74 (95% CI, 0.67-0.82), 1.78 (95% CI, 1.29-2.44), 4.22 (95% CI, 2.94-6.05) and 5.08 years (95% CI, 2.39-10.79) in the four subsequent therapy eras, respectively. Inferences on the beneficial effects of HAART were confirmed after adjustment by age, sex, type of AIDS diagnosis and CD4 cell count at diagnosis. The pattern of the hazard of death after AIDS changed from increasing in the pre-HAART era to being lower and non-increasing in the eras of HAART. Conclusions: The sustained beneficial effect of HAART, even in individuals with clinical AIDS and extensive treatment histories, attenuates concerns about emergence of resistance but augurs that a substantial number of HIV-infected individuals may require care for very long periods.

KW - AIDS

KW - Effectiveness

KW - HAART

KW - Hazard

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=27944439713&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27944439713&partnerID=8YFLogxK

M3 - Article

VL - 19

SP - 2009

EP - 2018

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 17

ER -